Davis et al. recently showed that the ATM inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil leads to tumor growth inhibition in CRC preclinical models, enhancing the limited effect of AZD0156 alone [57]. The gene discussed is ATM; the disease is colorectal carcinoma.